# Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
Canonical URL: https://biopharmsignal.com/news/RLMD/relmada-therapeutics-to-report-second-quarter-2026-financial-results-on-thursday-a5332b5c
Ticker: RLMD
Company: Relmada
Source: Relmada
Published: 2026-07-16 11:05 EST
Original Source URL: https://www.relmada.com/for-investors/news/detail/343/relmada-therapeutics-to-report-second-quarter-2026
## Summary

CORAL GABLES, Fla., July 16, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”),…...

## Article Body
Jul 16, 2026 7:05 AM EDT

CORAL GABLES, Fla., July 16, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced plans to host a conference call and webcast on Thursday, August 6, 2026 at 4:30 PM ET to discuss financial results for the second quarter ended June 30, 2026, and recent business progress.

Conference Call and Webcast Information:

Date: Thursday, August 6, 2026 at 4:30 PM ET

Participant Dial-in (US): 1-800-717-1738

Participant Dial-in (International): 1-646-307-1865

Webcast Access: Click Here

A replay of the webcast will be available in the Investors section of the Relmada website at https://www.relmada.com/investors/ir-calendar .

About Relmada Therapeutics, Inc. Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology and central nervous system conditions. Its lead candidates, NDV-01 and sepranolone, are advancing through mid-stage clinical development with the potential to address significant unmet needs.

For more information, visit www.relmada.com

Investor Contact: Brian Ritchie LifeSci Advisors britchie@lifesciadvisors.com

Media Inquiries: Corporate Communications media@relmada.com

Source: Relmada Therapeutics

Released July 16, 2026
## Recent Company News
- 2026-07-16 11:05 EST — [Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026](https://biopharmsignal.com/news/RLMD/relmada-therapeutics-to-report-second-quarter-2026-financial-results-on-thursday-a5332b5c) — Source: Relmada
- 2026-06-29 11:00 EST — [Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes](https://biopharmsignal.com/news/RLMD/relmada-therapeutics-joins-russell-2000-and-russell-3000-indexes-f3211c84) — Source: Relmada
- 2026-06-25 13:46 EST — [Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program](https://biopharmsignal.com/news/RLMD/relmada-therapeutics-appoints-cns-drug-development-veteran-michael-quirk-as-senior-advisor-for-sepranolone-program) — Source: Relmada
- 2026-06-25 13:46 EST — [Relmada Therapeutics to Present at the Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/RLMD/relmada-therapeutics-to-present-at-the-jefferies-global-healthcare-conference) — Source: Relmada
- 2026-06-25 13:46 EST — [Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/RLMD/relmada-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-update) — Source: Relmada
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)